Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lies and more lies, first by so called management, then by self serving pumpers. The SEC knows about all of them :).
Yep, he trys to warn newbies of all the lies spouted by ex SLJB scamsters and scamsters who post on this board.
Charters-how low does the retrace look like its going? TIA.
Looks like another crook in congress may walk a "bridge to nowhere except prison".
http://www.cbsnews.com/stories/2007/07/30/politics/main3115970.shtml?source=mostpop_story#ccmm
Mods;please take back this board from the same spammers posting redundant posts over and over. TIA.
Drug May Help Prevent Women's Osteoarthritis
07.30.07, 12:00 AM ET
MONDAY, July 30 (HealthDay News) -- Preliminary research in rats suggests that an existing drug could help older women stop osteoarthritis in its tracks.
The drug, known as calcitonin, is currently used to treat osteoporosis. According to tests in female rats, it shows promise as a possible treatment for osteoarthritis in older, postmenopausal women.
Patients "should be hopeful," said study co-author Morten A. Karsdal, head of pharmacology at Nordic Bioscience, a biotech company that is studying the drug's prospects as an arthritis treatment.
However, testing in humans won't end for another three years, and there's no guarantee that the drug will work as well in humans as in rats.
The study is published in the August issue of the journal Arthritis & Rheumatism.
Osteoarthritis affects an estimated 10 percent of Americans, and 80 percent of those over 55; women are especially vulnerable.
Hips and knees can be especially susceptible, said Dr. J.C. Gallagher, director of the Bone Metabolism Unit at Creighton University Medical School in Omaha, Neb. "For many, pain on exercise is the major problem. As a result, they stop exercising, and this leads to an increase in body weight which increases the 'load' on the joints and worsens the arthritis."
There are numerous treatments to relieve osteoarthritis pain but none to stop the wear and tear on the bone, joints and cartilage.
Karsdal said it is important to treat both loss of bone and loss of cartilage, the elastic tissue that helps bones tolerate moving against each other. "When bone turnover increases after menopause, due to lower estrogen production, a secondary effect is seen on cartilage, more cartilage is lost," Karsdal said. "Ideally, all drugs that may be developed for osteoarthritis will be able to affect both bone and cartilage, as both are in disequilibrium in osteoarthritis."
In the new study, researchers removed the ovaries of female rats, turning them into rough equivalents of postmenopausal women -- at least when it comes to their skeletons.
Some of the rats received calcitonin or estrogen, while some got nothing; a separate group of rats had no ovary operation.
The researchers found that calcitonin worked better than estrogen at preventing joint deterioration.
"The suggestion from this work is that estrogen deficiency after menopause is important," said Gallagher, who's familiar with the study findings.
Calcitonin is currently available as a nasal spray and an injection, although those forms haven't been investigated as possible osteoarthritis treatments, Karsdal said. In the United States, doctors can use approved drugs for "off-label" uses that are not recommended.
The oral form, which was tested in the study, is not on the market.
The next step in research is to investigate whether calcitonin could bring the development of osteoarthritis to a halt, Karsdal said. Two ongoing studies in humans should hopefully "provide a novel and effective treatment for osteoarthritis," although they won't be finished for three years, Karsdal said.
"Figures, transparancy is a problem for the company and others."
Yep,you got that right, lies are always a problem for companies in the end.
What happened to your .21 (sell at .19) target of two weeks ago,lol?
Yeah, and why has 2C completely vanished from both boards?
Two new BIPH medical patents:
http://www.eplabdigest.com/article/5904
Also, another BIPH article-2 new medical patents:
http://www.eplabdigest.com/article/5904
Biophan Technologies, Inc. (BIPH) shares doubled today previously at $0.205 up 100% at $0.41 with 1,340,373 shares traded. (BIPH) was highlighted today by HotOTC.com and StockEgg.com
Biophan Technologies, Inc. announced that Earlier this year, the New England Journal of Medicine published a study that focused on the function and effectiveness of MRI in the detection of breast cancer, but many patients with many implantable devices still cannot undergo MRIs. According to the company CEO Michael Weiner "the trouble lies with the implanted leads, which contain metal wires that connect the devices to tissue, as well as other metallic devices that act as antennas and absorb energy from the MRI machine." This can cause the tissue near the lead to heat up as well as generate voltages that can cause potentially fatal arrhythmias. The patented technologies developed by Biophan can be built into leads and devices to reduce heating and induced voltages to safe levels. Recognizing that different devices have varying design requirements, the company has developed a wide range of innovative solutions designed for various types of implants.
Biophan Technologies, Inc. engages in the development and commercialization of technologies for use with medical procedures and biomedical devices.
http://www.transworldnews.com/NewsStory.aspx?storyid=19536&ret=Default.aspx
BIPH moving up past few days. Anyone know why?
She doesnt seem to be the type who wears a tinfoil hat.
PBLS Q1 results:
MADISONVILLE, LA -- 07/25/07 -- Phoenix Associates Land Syndicate (Phoenix) (PINKSHEETS: PBLS) today announced its Q1-2007 financial results. The Company reported consolidated (unaudited) revenues for the quarter ended March 31, 2007 of $48,143,531, with pretax income of $1,994,279.
Phoenix consolidated operating results for the first quarter of 2007 reflected solid performances in all divisions. Year to year results, exclusive of acquisitions, experienced steady growth. Noble Jet of Ft. Lauderdale, FL, was acquired in February 2007, and contributed immediate bottom line results to the aviation division. 2007 revenue for Noble should exceed $2 million, with operating income in the 20% range.
Mining operations, after infrastructure completion and ramp up of operations were productive. Construction and swimming pool operations, though cyclical, appear to be headed toward a record year. Oil and Gas exploration, through Ideal Energy Directional Drilling, reported record revenues for the quarter, with more drilling infrastructure being put in place. Historically this entity provides a 20% to 25% level of operating income. Sam's Oil Country Services has also experienced consistent growth both in revenues and operating income. Aviation fuel sales in the first quarter remained strong, not missing a step prior to the planned move of the operation to Houston in May 2007. Aviation sales and maintenance continue to take steps to increase sales and profitability, while providing solid results.
Phoenix looks forward to solid and consistent growth from continuing operation in 2007, along with immediate contributions from all recent acquisitions. The management of Phoenix feels that shareholders will be rewarded in 2007 by the continuing commitment to growing not only revenues and profitability, but shareholder value.
Phoenix will be providing these operating results to Pink Sheets ahead of the specified deadline of August 1, 2007, and will continue on the path toward transparent reporting in a systematic and structured manner.
Phoenix Associates Land Syndicate, Inc.
Consolidated Balance Sheet - (Unaudited)
----------------------------------------
March 31, 2007 and December 31, 2006
Q1-2007 2006
----------- -----------
ASSETS
Current Assets
Cash and Cash Equivalents 3,151,246 9,202,005
Accounts receivable - net 13,418,747 4,496,621
Inventories 11,840,043 13,041,050
----------- -----------
Total Current Assets 28,410,036 26,739,676
Other Assets
Investment 19,350,088 18,250,088
Prepaid Expenses 430,753 282,047
Goodwill 13,632,540 13,232,540
Oil Reserves 0 0
Land Leases 1,402,840 1,402,840
----------- -----------
Total Other Assets 34,816,221 33,167,515
Fixed Assets
Buildings 728,000 728,000
Land 225,000 225,000
Real Estate Holdings 11,002,642 11,002,642
Building Improvements 433,017 412,268
Machinery & Equipment 9,432,016 9,397,825
Furniture & Fixtures 208,345 177,065
Leasehold Improvements 18,549,000 18,549,000
Mineral Reserves 47,550,000 47,550,000
Vehicles 296,384 275,531
Less: Accum Depletion (17,057,950) (16,015,635)
Less: Accum Depreciation (7,222,125) (6,780,821)
----------- -----------
Total Fixed Assets - Net 64,144,329 65,520,875
TOTAL ASSETS 127,370,586 125,428,066
=========== ===========
LIABILITIES & SHAREHOLDERS' EQUITY
Current Liabilities 20,950,047 28,543,162
Long Term Liabilities 10,355,090 4,107,000
Shareholders' Equity
Stock & Paid in Capital 85,387,974 84,113,032
Unrealized Market Gain / (Loss) 3,883 (14,441)
Retained Earnings 8,679,313 (158)
Income / (Loss) 1,994,279 8,679,471
----------- -----------
96,065,449 92,777,904
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY 127,370,586 125,428,066
=========== ===========
Phoenix Associates Land Syndicate, Inc.
Consolidated Statement of Operations (Unaudited)
------------------------------------------------
Three Months
Ended
March 31, 2007
--------------
Revenues 48,143,531
Costs of Goods Sold 41,746,218
--------------
Gross Profit 6,397,313
Operating Expenses 2,944,116
Operating Profit. (Loss) before 3,453,197
Depr, Amort, Depl, Interest & Tax
Depr, Amort, Depl, Interest & Tax 1,483,637
Other Income / (Expenses) 24,719
Income / (Loss) -- Pretax 1,994,279
==============
Notes: The above data was prepared internally by management
About Phoenix Associates Land Syndicate
Phoenix Associates Land Syndicate (PBLS) is a public holding company, with thousands of stockholders, that has purchased motivated companies in order to enhance its assets and income basis. Since 1978, PBLS has developed assets and/or interests in aviation, sand & gravel, soil products, land development, oil and natural gas, commodity brokering, plumbing, trucking, contract hauling, construction, swimming pool construction and construction related industries. For more information, visit www.pbls.biz
Forward-Looking Statements
This press release contains statements that are "forward looking" and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Generally, the words "expect," "intend," "estimate," "will" and similar expressions identify forward-looking statements. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements, or that of our industry, to differ materially from those expressed or implied in any of our forward-looking statements. Statements in this press release regarding the Company's business or proposed business, which are not historical facts, are "forward-looking" statements that involve risks and uncertainties, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.
For More Information Contact:
Mike Mulshine
Osprey Partners
(732) 292-0982
osprey57@optonline.net
Yeah after reading this post on another board, I would vote for him,lol. He also probably has a relative doing the AF's too.
By: the_gaffer
25 Jul 2007, 07:35 PM EDT
Msg. 17317 of 17318
(This msg. is a reply to 17308 by puffalump.)
Jump to msg. #
puff, snips pulled the same stunt when he was shilling for QBID. He and the other pumpers even got the IR guy to post on RB that the company was going to sue critics. QBID put out a PR making the same bogus claims as snips and QBID IR. What resulted was snips pumping QBID to zero bid, the SEC requesting info from the IR guy, the company liquidating, going BK, the TA quitting and no more trading of the company's shares. So much for snips. ;0)
I agree it's ludicrous. That's why I want Slo to post his proof. Snips should post his proof. It is all BS if you ask me, They need to be held accountable for giving shareholders this fasle info, especially via PM on a messsage board to select shareholders only. Maybe the company wanted Snips to post the info as he said, so that HE would be held accountable. I think they are using him, like they did Rick, only Snips is stupid, and will look like a bigger fool than he already is.When it all comes falling down, Snips will have to answer to alot of angry people on his message board!!
You mean like peetard used to give us?
Ohboy,here we go again,lol.
Hey what happened to all my spam/scam mail the last few days? Havent gotten any. Perhaps our forwards to SEC,etc got some action????
MOSCOW, Jul 25, 2007 (MARKET WIRE via COMTEX) -- NWOG Inc. (PINKSHEETS: NWOG)
together with the CJSC "North-West Oil Group" (Russia) have obtained all
necessary permissive documents for drilling of the second well at the Shalinsky
license field and is planning to start with the drilling early in August. After
completion of the drilling, production rate will amount as predicted
approximately to 5694 barrels a month of total stock volume of 10,950,000
barrels.
About North West Oil Group (formerly Nord Oil International): North West Oil
Group is a non-reporting, publicly traded Oil & Gas company trading under the
ticker symbol NWOG on the U.S. Pinksheets market.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical
facts are forward-looking statements, which contain our current expectations
about our future results. Forward-looking statements involve numerous risks and
uncertainties. We have attempted to identify any forward-looking statements by
using words such as "anticipates," "believes," "could," "expects," "intends,"
"may," "should" and other similar expressions. Although we believe that the
expectations reflected in all of our forward-looking statements are reasonable,
we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to
differ materially from those indicated in any forward-looking statements made by
us or on our behalf. Such factors include our limited operating history; our
need for significant capital to finance internal growth as well as strategic
acquisitions; our ability to attract and retain key employees and strategic
partners; our ability to achieve and maintain profitability; fluctuations in the
trading price and volume of our stock; competition from other providers of
similar products and services; and other unanticipated future events and
conditions.
What is so funny is the Kool-Aid drinkers still believe this SLJB "PR"and swear by it,lol.
Hey 2C, are you still on your business "trip"? Did you find another company to invest in? TIA.
IPS Signs Contract With Coalition America, The Nation's Leader In Medical Claim Savings
9:25a ET July 23, 2007 (PR NewsWire)
Integrated Pain Solutions, LLC (IPS), a wholly owned subsidiary of PainCare Holdings, Inc. (Amex: PRZ), today announced that it has signed an agreement with Coalition America, Inc. (CAI), the nation's leader in medical claim savings, to assist CAI in cost containment programs and pain-related medical treatment for those patients associated with CAI's national customer base of employers, insurers, payors, HMOs, re-insurers and managing general underwriters.
The National Institutes of Health reports that the cost of chronic pain in the United States, including healthcare expenses, lost income and lost productivity, is estimated to be over $500 billion per year. Scott Smith, president of CAI, stated, "With the medical component and related economic exposure of healthcare on the rise, the industry has been challenged to create and execute more effective healthcare cost management strategies that create true win-win scenarios for payors, providers, employers and employees. IPS' novel managed services approach to the treatment of pain is both timely and in keeping with prevailing industry demand for innovative cost control solutions. Consequently, we are looking forward to working with IPS to help deliver material savings to our valued clients."
Maria McAfee, President of IPS, noted, "Serving over 250 clients who represent thousands of health plans impacting millions of lives nationwide, CAI is playing a key proactive role in helping to positively impact economic exposure while enhancing access to care for patients. IPS is very proud to have Coalition America as a client and expect that this new relationship will result in tangible cost savings for CAI's customers and an important new revenue channel for IPS in the coming year."
About Coalition America, Inc.
Coalition America, Inc. (CAI) is the leader in medical claim savings utilizing proprietary technology, PPOs (preferred provider organizations) and negotiations to deliver significant discounts on group health and workers' compensation medical bills. Clients interface with CAI through HIPAA compliant EDI (electronic data interchange) or the Internet to reprice in- network and out-of-network medical claims. CAI generates significant savings through the integration of Primary PPOs, Wrap PPOs, Supplemental PPOs, and direct provider negotiations.
The Atlanta-based healthcare savings company directly services over 250 clients representing more than 50,000 businesses nationwide. CAI has saved its clients over one billion dollars since its inception in 1995. For more information about Coalition America please visit www.coalitionamerica.com.
About Integrated Pain Solutions (IPS)
Integrated Pain Solutions (IPS), a wholly-owned subsidiary of PainCare Holdings, Inc., is the first and only managed services organization offering a multidisciplinary healthcare network focused on pain management to payor organizations, such as insurance and workers' compensation carriers and unions. IPS reduces costs and increases quality of life by providing highly credentialed physicians and centers of excellence on pay-for-performance incentives, a continuum of care that begins with care coaching, a shared financial and clinical data warehouse, and evidence-based clinical outcome measurements to determine the most effective pain-management plan. For more information, please visit www.integratedpainsolutions.net.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first Managed Services Organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
Safe Harbor Statement
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT: Media Relations Suzanne Beranek, APR, Beranek Communications, LLC 407-475-0763 or via email at suzanne@beranekcommunications.com FOR MORE INFORMATION, PLEASE CONTACT: Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist Elite Financial Communications Group 407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
Media Relations: Suzanne Beranek, APR, Beranek Communications, LLC, +1-407-475-0763, suzanne@beranekcommunications.com; Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist, Elite Financial Communications Group, +1-407-585-1080, prz@efcg.net
http://www.paincareholdings.com/
IPS Signs Contract With Coalition America, The Nation's Leader In Medical Claim Savings
9:25a ET July 23, 2007 (PR NewsWire)
Integrated Pain Solutions, LLC (IPS), a wholly owned subsidiary of PainCare Holdings, Inc. (Amex: PRZ), today announced that it has signed an agreement with Coalition America, Inc. (CAI), the nation's leader in medical claim savings, to assist CAI in cost containment programs and pain-related medical treatment for those patients associated with CAI's national customer base of employers, insurers, payors, HMOs, re-insurers and managing general underwriters.
The National Institutes of Health reports that the cost of chronic pain in the United States, including healthcare expenses, lost income and lost productivity, is estimated to be over $500 billion per year. Scott Smith, president of CAI, stated, "With the medical component and related economic exposure of healthcare on the rise, the industry has been challenged to create and execute more effective healthcare cost management strategies that create true win-win scenarios for payors, providers, employers and employees. IPS' novel managed services approach to the treatment of pain is both timely and in keeping with prevailing industry demand for innovative cost control solutions. Consequently, we are looking forward to working with IPS to help deliver material savings to our valued clients."
Maria McAfee, President of IPS, noted, "Serving over 250 clients who represent thousands of health plans impacting millions of lives nationwide, CAI is playing a key proactive role in helping to positively impact economic exposure while enhancing access to care for patients. IPS is very proud to have Coalition America as a client and expect that this new relationship will result in tangible cost savings for CAI's customers and an important new revenue channel for IPS in the coming year."
About Coalition America, Inc.
Coalition America, Inc. (CAI) is the leader in medical claim savings utilizing proprietary technology, PPOs (preferred provider organizations) and negotiations to deliver significant discounts on group health and workers' compensation medical bills. Clients interface with CAI through HIPAA compliant EDI (electronic data interchange) or the Internet to reprice in- network and out-of-network medical claims. CAI generates significant savings through the integration of Primary PPOs, Wrap PPOs, Supplemental PPOs, and direct provider negotiations.
The Atlanta-based healthcare savings company directly services over 250 clients representing more than 50,000 businesses nationwide. CAI has saved its clients over one billion dollars since its inception in 1995. For more information about Coalition America please visit www.coalitionamerica.com.
About Integrated Pain Solutions (IPS)
Integrated Pain Solutions (IPS), a wholly-owned subsidiary of PainCare Holdings, Inc., is the first and only managed services organization offering a multidisciplinary healthcare network focused on pain management to payor organizations, such as insurance and workers' compensation carriers and unions. IPS reduces costs and increases quality of life by providing highly credentialed physicians and centers of excellence on pay-for-performance incentives, a continuum of care that begins with care coaching, a shared financial and clinical data warehouse, and evidence-based clinical outcome measurements to determine the most effective pain-management plan. For more information, please visit www.integratedpainsolutions.net.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first Managed Services Organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
Safe Harbor Statement
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT: Media Relations Suzanne Beranek, APR, Beranek Communications, LLC 407-475-0763 or via email at suzanne@beranekcommunications.com FOR MORE INFORMATION, PLEASE CONTACT: Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist Elite Financial Communications Group 407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
Media Relations: Suzanne Beranek, APR, Beranek Communications, LLC, +1-407-475-0763, suzanne@beranekcommunications.com; Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist, Elite Financial Communications Group, +1-407-585-1080, prz@efcg.net
http://www.paincareholdings.com/
>
> I AGREE........
> Written by a housewife from New Jersey and it sounds like this is one pissed
off lady.
>
> Are we fighting a war on terror or aren't we?
>
> Was it or was it not started by Islamic people who brought it to our shores on
September 11, 2001?
>
> Were people from all over the world, mostly Americans, not brutally murdered
that day, in downtown Manhattan, across the Potomac from our nation's capitol
and in a field in Pennsylvania ?
>
> Did nearly three thousand men, women and children die a horrible, burning or
crushing death that day, or didn't they?
>
> And I'm supposed to care that a copy of the Koran was "desecrated" when an
overworked American soldier kicked it or got it wet?...
> Well, I don't. I don't care at all.
>
> I'll start caring when Osama bin Laden turns himself in and repents for
incinerating all those innocent people on 9/11.
>
> I'll care about the Koran when the fanatics in the Middle East start caring
about the Holy Bible, the mere possession of which is a crime in Saudi Arabia
>
> I'll care when these thugs tell the world they are sorry for hacking off Nick
Berg's head while Berg screamed through his gurgling slashed throat.
>
> I'll care when the cowardly so-called "insurgents" in Iraq come out and fight
like men instead of disrespecting their own religion by hiding in mosques.
>
> I'll care when the mindless zealots who blow themselves up in search of
nirvana care about the innocent children within range of their suicide bombs.
>
> I'll care when the American media stops pretending that their First Amendment
liberties are somehow derived from international law instead of the United
States Constitution's Bill of Rights.
>
> In the meantime, when I hear a story about a brave Marine roughing up an Iraqi
terrorist to obtain information,
> know this: I don't care!
>
> When I see a fuzzy photo of a pile of naked Iraqi prisoners who have been
humiliated in what amounts to a college-hazing incident,
> rest assured: I don't care!
>
> When I see a wounded terrorist get shot in the head when he is told not to
move because he might be booby-trapped,
> you can take it to the bank: I don't care!
>
> When I hear that a prisoner, who was issued a Koran and a prayer mat, and fed
"special" food that is paid for by my tax dollars, is complaining
> that his holy book is being "mishandled,"
> you can absolutely believe in your heart of hearts: I don't care!
>
> And oh, by the way, I've noticed that sometimes it's spelled "Koran" and other
times "Quran."
> Well, Jimmy Crack Corn and -you guessed it -I don't care ! ! ! ! !
>
> If you agree with this viewpoint, pass this on to all your e-mail friends.
?Sooner or later, it'll get to the people responsible for this
> ridiculous behavior!
>
> If you don't agree, then by all means hit the delete button. Should you choose
the latter, then please don't complain when more atrocities committed by radical
Muslims happen here in our great country!
>
> And may I add:
>
> "Some people spend an entire lifetime wondering if they made a
> difference in the world. But, the Marines don't have that problem."
> -- Ronald Reagan
>
> I have another quote that I would like to add AND.......I hope you forward all
this.
>
> "If we ever forget that we're One Nation Under God,
> then we will be a nation gone under."
> also by.. Ronald Reagan
>
> One last thought for the day:
>
> In case we find ourselves starting to believe all the anti-American sentiment
and negativity, we should remember England 's Prime Minister Tony Blair's words
during a recent interview. When asked by one of his Parliament members why he
believes so much in America , he said:
> "A simple way to take measure of a country is to look at how many want
in...And how many want out."
>
> Only two defining forces have ever offered to die for you:
> 1. Jesus Christ
> 2. The American G. I.
> One died for your soul, the other for your freedom
> YOU MIGHT WANT TO PASS THIS ON, AS MANY SEEM TO FORGET BOTH OF THEM.
> AMEN!
>
Roche and BioCryst Advance BCX-4208/R3421 Into Phase II Psoriasis Trial
7:00a ET July 16, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of the first Phase II study to evaluate BCX-4208/R3421. This clinical trial, led by Roche, is designed to evaluate BCX-4208 in patients with moderate to severe plaque psoriasis.
BCX-4208 is an orally available small molecule inhibitor of purine nucleoside phosphorylase (PNP), an enzyme that is essential for the proliferation of activated T cells. With its novel mechanism of action BCX- 4208 has the potential to address unmet medical needs across a broad spectrum of autoimmune diseases as well as in the area of acute transplant rejection.
Through the initiation of this Phase II clinical trial, Roche and BioCryst continue to demonstrate their strong commitment to develop BCX-4208 as a novel agent to improve therapeutic options for patients with debilitating autoimmune conditions.
"We are excited that BCX-4208 is advancing into Phase II testing," said Jon P. Stonehouse, CEO of BioCryst. "The potential for a new oral therapy that is convenient, safe and effective would be an important addition to currently available treatment options for the many millions of patients who suffer from serious autoimmune conditions around the world. BCX-4208 is the lead compound in our second generation PNP inhibitor program and the initiation of this trial represents a significant step towards demonstrating proof-of-concept with this promising approach in important disease areas."
About the Phase II Trial
Phase I single ascending dose and multiple ascending dose trials in healthy volunteers were successfully completed in 2006. The Phase II study announced today is a double-blind, placebo-controlled randomized trial, comprised of three arms, each enrolling 20 patients for a total of 60 patients with moderate to severe psoriasis. Two arms will receive active drug in different dosage strengths, while patients in the third arm will receive placebo. Patients in all three arms will be dosed once daily for six weeks. The study will be conducted at multiple centers across the U.S.
About BCX-4208
BCX-4208, a second generation transition-state analog inhibitor of the enzyme purine nucleoside phosphorylase (PNP), may have the potential to offer greater efficacy and activity in the treatment of autoimmune disease and transplant rejection than currently available therapies.
In 2005, BioCryst announced a partnership with Roche for the development and commercialization of BCX-4208 for transplantation and autoimmune diseases. Roche holds exclusive worldwide rights to BCX-4208 and BioCryst retains co- promotion rights in the U.S. for several indications.
About Psoriasis
Psoriasis, a chronic and often painful and debilitating autoimmune disease, affects an estimated 2-3 percent of the world's population, accounting for nearly 125 million persons worldwide. The National Institutes of Health estimates that 5.8-7.5 million Americans have psoriasis and between 10-30 percent of people with psoriasis will later develop psoriatic arthritis.
Psoriasis occurs when faulty signals in the immune system mistakenly activate T-cells causing inflammation and resulting in the faster-than-normal regeneration of skin cells. Usually skin cell regeneration takes about a month, in the presence of psoriasis the skin regenerates in a few days. This overabundance of skin cells results in patches of thick, red skin which can cause significant physical discomfort. These patches of skin, called plaques, occur most often on the elbows, knees, scalp, face, palms and soles of the feet but they can appear anywhere on the body including the fingernails, toenails and the soft tissues of the genitals and inside the mouth.
About Autoimmune Diseases
Autoimmune diseases occur when the immune system attacks the body's own cells rather than invading microorganisms. There are more than 80 clinically distinct autoimmune diseases (i.e. multiple sclerosis, rheumatoid arthritis and some types of diabetes), each affecting the body in different ways. Presentation of these diseases can also vary from patient to patient with the same condition, and can lead to organ failure requiring transplantation. Corticosteroids are still the mainstay of treatment for many autoimmune diseases and physicians have to constantly balance the requirement for best possible disease control with the drug related morbidities associated with long term steroid exposure.
About Transplant Rejection
The greatest threat to transplant patients is rejection of the transplanted organ by the body's own immune system. For this reason, transplant recipients must take drugs to suppress the immune response and prevent rejection usually for the rest of their lives. A regimen combining several drugs is usually given and this treatment has to be continued indefinitely. Rejection of the new kidney by the patient's immune system can lead to loss of the transplanted organ and a return to dialysis for kidney transplant recipients. For heart, lung and liver transplant patients, loss of the transplanted organ presents an immediate threat to life.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.
Forward-looking statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we may not be able to commence the proposed Phase III trial for peramivir within the time frame we currently expect or at all, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.
Contact: BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633
SOURCE BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent, V.P. Corporate Communications, BioCryst Pharmaceuticals, Inc., +1-205-444-4633
http://www.biocryst.com
BioCryst Receives Special Protocol Assessment for Pivotal Trial of Oral Fodosine(TM) in Patients With Cutaneous T-Cell Lymphoma (CTCL)
7:00a ET July 9, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the FDA's Special Protocol Assessment (SPA) process for the design of its planned pivotal clinical trial of the oral formulation of the company's lead oncology compound, Fodosine(TM) (forodesine hydrochloride) in patients with cutaneous T-cell lymphoma.
A Special Protocol Assessment is a request for feedback from the FDA that allows a company to receive official evaluation and guidance on the design of pivotal trial protocols. BioCryst requested the formal assessment, late in the first quarter of 2007, because the pivotal trial is intended to form the primary basis of an efficacy claim in the planned new drug application (NDA) for oral Fodosine.
The multicenter, multinational, open-label, single-arm, repeat-dose pivotal trial is expected to initiate enrollment during the third quarter of 2007. The trial will enroll patients with CTCL of Stage IB through Stage IVA who have disease that is persistent, progressive or recurrent during or after treatment with at least three systemic therapies. The study's primary endpoint is to determine the objective response rate, defined as either complete response or partial cutaneous response, achieved with a once-daily oral regimen of Fodosine(TM). Secondary endpoints include assessing the safety and tolerability of extended daily treatment with oral Fodosine(TM), assessment of the time to objective response and the duration of objective response.
"We are pleased to have reached agreement with the FDA in a timely manner. Receipt of this SPA is an important milestone in the development of Fodosine(TM) and a sign of our commitment to deliver on our goals," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "We would like to thank the FDA for their input and guidance during this SPA process. BioCryst is now well positioned to begin patient enrollment during the third quarter."
About Fodosine(TM)
Fodosine(TM) is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL), B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL).
In early 2006, BioCryst entered into a strategic collaboration with Mundipharma International Holdings Limited to develop and commercialize Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries for use in oncology.
About BioCryst
LAKE OSWEGO, Ore., July 23 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today the results, including positive cost and social implications, of a field evaluation of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in Tanzania. The results of the evaluation are being presented this week in a poster at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia. Posters are scientific research publications presented in a display form for broad audience viewing, and have the advantage of providing an opportunity for extensive interaction between conference attendees and the poster authors.
The field evaluation was conducted on 1,055 clients at the African Medical & Research Foundation ("AMREF") ANGAZA Voluntary Counseling and Testing ("VCT") centers in Tanzania, a Non-Government Organization ("NGO"). ANGAZA is one of AMREF's primary projects in Tanzania; its objectives are to increase access to quality counseling for VCT centers as an entry to a continuum of HIV/AIDS care and prevention and to establish community care support for HIV positive clients. Of the clients tested at the ANGAZA center, 12%, or 123 clients, tested positive for HIV. The poster reported that the accuracy of the Aware(TM) HIV-1/2 OMT test was 100%, better than that of a comparable rapid blood test. (Calypte's rapid blood test was not evaluated in this study.). The poster also concluded that the evaluation "yielded a significant reduction in the cost of testing."
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "We believe that oral fluid testing using our Aware(TM) HIV-1/2 OMT test will become the standard of care in many settings based on its continued strong clinical results coupled with the social and cost advantages of oral fluid testing. Our internal research has determined that the overall cost of oral fluid testing is less than that of blood testing. Oral fluid testing permits a healthcare worker to educate a group of clients simultaneously rather than requiring the individual attention demanded by all blood tests due to the administration, and blood handling and disposal requirements of blood-based tests. This is a significant advantage in resource-constrained settings requiring high client throughput. There are no other costs required to perform an oral fluid test and oral fluid has the obvious advantages of safety for both the client and healthcare worker and no hazardous disposal issues."
"We look forward to continuing to work with important NGOs like AMREF in Tanzania and elsewhere. We plan to support AMREF in their efforts to validate other aspects of HIV oral fluid rapid testing," Mr. Gale continued.
Mr. David Ocheng, a Medical Laboratory Technologist and project manager of AMREF who coordinated the field evaluation at ANGAZA elaborated, "We questioned the over 1,000 clients in this study on whether they would prefer a blood test or an oral fluid test, and, although they had consented to both for this to be a valid study, over 76.7% responded that they would prefer the oral procedure. We expect to now follow this question with a formal study on acceptance and welcome Calypte's support for this project. We believe acceptance of oral fluid testing has important implications, as our ability to increase the testing rate will have a direct correlation with our ability to then treat and care for HIV positive individuals. Ultimately, this is the best alternative screening method to support efforts to control the epidemic -- a very important goal of all of us involved in Tanzania."
Professor Willy Urassa of Muhimbili University College of Health Sciences in Tanzania ("MUCHS"), the lead investigator of this field study, commented, "Our study concluded that the test is indeed more cost effective than a blood test. This is one of the elements that would influence policy and decision makers in considering alternative rapid testing methods in the country. The results of sensitivity and specificity cannot be overemphasized, but when one considers overall cost, safety and acceptance, what will be left is to educate the public on the existence of alternative rapid testing methods through proper Government channels."
"We see that in many settings oral fluid testing can and should become the test of choice," Professor Urassa concluded.
LAKE OSWEGO, Ore., July 23 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today the results, including positive cost and social implications, of a field evaluation of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in Tanzania. The results of the evaluation are being presented this week in a poster at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia. Posters are scientific research publications presented in a display form for broad audience viewing, and have the advantage of providing an opportunity for extensive interaction between conference attendees and the poster authors.
The field evaluation was conducted on 1,055 clients at the African Medical & Research Foundation ("AMREF") ANGAZA Voluntary Counseling and Testing ("VCT") centers in Tanzania, a Non-Government Organization ("NGO"). ANGAZA is one of AMREF's primary projects in Tanzania; its objectives are to increase access to quality counseling for VCT centers as an entry to a continuum of HIV/AIDS care and prevention and to establish community care support for HIV positive clients. Of the clients tested at the ANGAZA center, 12%, or 123 clients, tested positive for HIV. The poster reported that the accuracy of the Aware(TM) HIV-1/2 OMT test was 100%, better than that of a comparable rapid blood test. (Calypte's rapid blood test was not evaluated in this study.). The poster also concluded that the evaluation "yielded a significant reduction in the cost of testing."
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "We believe that oral fluid testing using our Aware(TM) HIV-1/2 OMT test will become the standard of care in many settings based on its continued strong clinical results coupled with the social and cost advantages of oral fluid testing. Our internal research has determined that the overall cost of oral fluid testing is less than that of blood testing. Oral fluid testing permits a healthcare worker to educate a group of clients simultaneously rather than requiring the individual attention demanded by all blood tests due to the administration, and blood handling and disposal requirements of blood-based tests. This is a significant advantage in resource-constrained settings requiring high client throughput. There are no other costs required to perform an oral fluid test and oral fluid has the obvious advantages of safety for both the client and healthcare worker and no hazardous disposal issues."
"We look forward to continuing to work with important NGOs like AMREF in Tanzania and elsewhere. We plan to support AMREF in their efforts to validate other aspects of HIV oral fluid rapid testing," Mr. Gale continued.
Mr. David Ocheng, a Medical Laboratory Technologist and project manager of AMREF who coordinated the field evaluation at ANGAZA elaborated, "We questioned the over 1,000 clients in this study on whether they would prefer a blood test or an oral fluid test, and, although they had consented to both for this to be a valid study, over 76.7% responded that they would prefer the oral procedure. We expect to now follow this question with a formal study on acceptance and welcome Calypte's support for this project. We believe acceptance of oral fluid testing has important implications, as our ability to increase the testing rate will have a direct correlation with our ability to then treat and care for HIV positive individuals. Ultimately, this is the best alternative screening method to support efforts to control the epidemic -- a very important goal of all of us involved in Tanzania."
Professor Willy Urassa of Muhimbili University College of Health Sciences in Tanzania ("MUCHS"), the lead investigator of this field study, commented, "Our study concluded that the test is indeed more cost effective than a blood test. This is one of the elements that would influence policy and decision makers in considering alternative rapid testing methods in the country. The results of sensitivity and specificity cannot be overemphasized, but when one considers overall cost, safety and acceptance, what will be left is to educate the public on the existence of alternative rapid testing methods through proper Government channels."
"We see that in many settings oral fluid testing can and should become the test of choice," Professor Urassa concluded.
Bones be careful of the pumpers on this board-they have pumped down from the .20's!
Overstock.com Wins Ruling in Prime Brokerage Litigation
PR Newswire
Court Gives Overstock.com the Okay to Proceed and Denies Prime Brokerages Attempts to Derail Exposure
July 18, 2007: 10:53 AM EST
SALT LAKE CITY, July 18 /PRNewswire-FirstCall/ -- Overstock.com, Inc. (http://www.overstock.com) announced today a favorable ruling in the lawsuit pending in the Superior Court of California, County of San Francisco against most of the largest prime brokerage firms in the country, including Morgan Stanley & Co. Incorporated, Goldman Sachs & Co., Bear Stearns Companies, Inc., Bank of America Securities LLC, Bank of New York, Citigroup Inc., Credit Suisse (USA) Inc., Deutsche Bank Securities, Inc., Merrill Lynch, Pierce, Fenner & Smith, Inc., and UBS Financial Services, Inc.
On July 17, 2007, Judge John Munter of the California Superior Court for the City and County of San Francisco ruled that Overstock and it co-plaintiffs have stated viable claims for market manipulation under California securities law, for common law claims for conversion and trespass to chattels, as well as for injunctive relief under California's Unfair Business Practices Act against the defendant prime brokerage firms based on those defendants allegedly executing naked short sales of the stock of Overstock with the intent of manipulating the market price for the shares of those companies' stocks. In addition, the Court granted Overstock (and its co-plaintiffs) leave to amend other of their claims for restitution under the Unfair Business Practices Act and for the common law claim of interference with advantage, to more specifically plead the factual basis of these claims.
In so ruling, Judge Munter rejected defendants' claims that Overstock's complaint is preempted by federal law and that 'phantom' shares are not created by naked short selling of a company's stock as a matter of law.
"This is a huge win for us," said Jonathan Johnson, Overstock Senior Vice President of Legal. "We are eager to start discovery and move this case to trial. The day we expose in detail the defendants' misconduct to a jury will be a good day for Overstock, its shareholders and the capital markets."
"As I listened to defendants' counsel argue that phantom shares don't exist because the SEC says they don't exist," said Patrick Byrne, Overstock Chairman and Chief Executive Officer, "I was reminded on Abraham Lincoln's favorite joke: 'If you call a tail a leg, how many legs does a dog have?' 'Five?' 'No, four -- because calling a tail a leg doesn't make it a leg.' Defendants create phantom shares by facilitating naked short selling and other types of trades which result in failures-to-deliver. This is manipulative and illegal -- regardless of what the industry's all-too-cozy regulatory agency says. The battle to clean up Wall Street is only going to be won when it is brought to a jury of 12 Americans. Today was a giant step towards that goal."
The suit alleges that the defendants, who control over 80% of the prime brokerage market, participated in a massive, illegal stock market manipulation scheme and that the defendants had no intention of covering such orders with borrowed stock, as they are required to do, causing what are referred to as "fails to deliver." The suit also alleges that the defendants' actions caused and continue to cause dramatic distortions with regard to the nature and amount of trading in the company's stock which have caused the share price of the company's stock to dramatically drop. The suit asserts that a persistent large number of "fails to deliver" creates large downward pressure on the price of a company's stock and that the amount of "fails to deliver" has exceeded the company's entire supply of outstanding shares. The company is seeking damages of $3.48 billion.
About Overstock.com
Overstock.com, Inc. is an online "closeout" retailer offering discount, brand-name merchandise for sale over the Internet. The company offers its customers an opportunity to shop for bargains conveniently, while offering its suppliers an alternative inventory liquidation distribution channel. Overstock.com, headquartered in Salt Lake City, is a publicly traded company listed on the NASDAQ National Market System and can be found online at http://www.overstock.com.
Overstock.com(R) is a registered trademark of Overstock.com, Inc. All other trademarks are the property of their respective owners.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, statements regarding statements regarding the case going to jury, defendants' exposure and the amount of damages that the company will seek, as well as all such other risks as identified in our Form 10-K for the year ended December 31, 2006, and all our subsequent filings with the Securities and Exchange Commission, which contain and identify important factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LAW07718072007-1.htm
Hope these (*&^%$* go to jail:
Overstock.com Wins Ruling in Prime Brokerage Litigation
PR Newswire
Court Gives Overstock.com the Okay to Proceed and Denies Prime Brokerages Attempts to Derail Exposure
July 18, 2007: 10:53 AM EST
SALT LAKE CITY, July 18 /PRNewswire-FirstCall/ -- Overstock.com, Inc. (http://www.overstock.com) announced today a favorable ruling in the lawsuit pending in the Superior Court of California, County of San Francisco against most of the largest prime brokerage firms in the country, including Morgan Stanley & Co. Incorporated, Goldman Sachs & Co., Bear Stearns Companies, Inc., Bank of America Securities LLC, Bank of New York, Citigroup Inc., Credit Suisse (USA) Inc., Deutsche Bank Securities, Inc., Merrill Lynch, Pierce, Fenner & Smith, Inc., and UBS Financial Services, Inc.
On July 17, 2007, Judge John Munter of the California Superior Court for the City and County of San Francisco ruled that Overstock and it co-plaintiffs have stated viable claims for market manipulation under California securities law, for common law claims for conversion and trespass to chattels, as well as for injunctive relief under California's Unfair Business Practices Act against the defendant prime brokerage firms based on those defendants allegedly executing naked short sales of the stock of Overstock with the intent of manipulating the market price for the shares of those companies' stocks. In addition, the Court granted Overstock (and its co-plaintiffs) leave to amend other of their claims for restitution under the Unfair Business Practices Act and for the common law claim of interference with advantage, to more specifically plead the factual basis of these claims.
In so ruling, Judge Munter rejected defendants' claims that Overstock's complaint is preempted by federal law and that 'phantom' shares are not created by naked short selling of a company's stock as a matter of law.
"This is a huge win for us," said Jonathan Johnson, Overstock Senior Vice President of Legal. "We are eager to start discovery and move this case to trial. The day we expose in detail the defendants' misconduct to a jury will be a good day for Overstock, its shareholders and the capital markets."
"As I listened to defendants' counsel argue that phantom shares don't exist because the SEC says they don't exist," said Patrick Byrne, Overstock Chairman and Chief Executive Officer, "I was reminded on Abraham Lincoln's favorite joke: 'If you call a tail a leg, how many legs does a dog have?' 'Five?' 'No, four -- because calling a tail a leg doesn't make it a leg.' Defendants create phantom shares by facilitating naked short selling and other types of trades which result in failures-to-deliver. This is manipulative and illegal -- regardless of what the industry's all-too-cozy regulatory agency says. The battle to clean up Wall Street is only going to be won when it is brought to a jury of 12 Americans. Today was a giant step towards that goal."
The suit alleges that the defendants, who control over 80% of the prime brokerage market, participated in a massive, illegal stock market manipulation scheme and that the defendants had no intention of covering such orders with borrowed stock, as they are required to do, causing what are referred to as "fails to deliver." The suit also alleges that the defendants' actions caused and continue to cause dramatic distortions with regard to the nature and amount of trading in the company's stock which have caused the share price of the company's stock to dramatically drop. The suit asserts that a persistent large number of "fails to deliver" creates large downward pressure on the price of a company's stock and that the amount of "fails to deliver" has exceeded the company's entire supply of outstanding shares. The company is seeking damages of $3.48 billion.
About Overstock.com
Overstock.com, Inc. is an online "closeout" retailer offering discount, brand-name merchandise for sale over the Internet. The company offers its customers an opportunity to shop for bargains conveniently, while offering its suppliers an alternative inventory liquidation distribution channel. Overstock.com, headquartered in Salt Lake City, is a publicly traded company listed on the NASDAQ National Market System and can be found online at http://www.overstock.com.
Overstock.com(R) is a registered trademark of Overstock.com, Inc. All other trademarks are the property of their respective owners.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include, but are not limited to, statements regarding statements regarding the case going to jury, defendants' exposure and the amount of damages that the company will seek, as well as all such other risks as identified in our Form 10-K for the year ended December 31, 2006, and all our subsequent filings with the Securities and Exchange Commission, which contain and identify important factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LAW07718072007-1.htm
Lol,lol. So no lawyer has ever gone to jail? So Parkin did not lie about NDOL? So Parkin would not lie about AURC,lol,lol?
I have a feeling that if Farkin Parkin does have his fingers in the pie, he had better NOT show up at the AURC shareholders meeting.
I suppose they are here to even out the false hopes of the pumpers!
Was'nt it snips that said on sljb board several months ago he had a relative doing the af's?
NEWS: Calypte Reports Positive Results of Aware(TM) HIV-1/2 Oral Fluid Rapid Test
Evaluation at 3rd Annual South African AIDS Conference
LAKE OSWEGO, Ore., July 16, 2007 /PRNewswire-FirstCall via COMTEX/ -- Calypte
Biomedical Corporation (CBMC), medical diagnostic tests manufacturer for the
rapid detection of antibodies to the human immunodeficiency virus (HIV) announced
today the results and positive social implications of a field evaluation of its
Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in the Republic of South Africa .
These results were recently presented in a poster at the 3rd South African AIDS
Conference in Durban last month. Posters are scientific research papers (in
poster presentation form) accepted by a conference for the education of its
attendees, typically displayed in a Poster Section on the conference floor.
The field evaluation was conducted on 600 clients of unknown HIV status at two
busy Voluntary Counseling and Testing ("VCT") clinics in South Africa. The
expected HIV prevalence rate was 30-40%; overall, 44% of the clients tested
positive. The poster reported that "the results obtained on OMT were comparable
with results on serum, and were statistically significant."
Study nurses responsible for the collection of samples described OMT (oral fluid
test) collection as "easy to do", and preferred the non-invasive oral fluid
collection method to the blood collection currently in use. Laboratory personnel
found the test procedure simple to perform and results easy to interpret. "This
assay may be a suitable alternative for VCT practices," was the poster's
conclusion.
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "We have long
known the accuracy of the Aware(TM) HIV-1/2 oral fluid rapid test. The usage
studies that are now being reported are focusing on the social aspects of such a
test and we are pleased that there is strong sentiment for adopting oral fluid
testing. While changing long-established blood collection practice to the OMT
method is a process, we believe we are gaining momentum in making oral fluid an
acceptable alternative to blood testing. The recent approval of our oral fluid
test in India and the subsequent interest we are seeing from the government,
military and private sectors is very encouraging in this regard."
Johannes Viljoen, MBChB, FC Path (SA) Viro, at the College of Health Sciences of
the University of KwaZulu-Natal, Durban, South Africa and principal investigator
presenting this poster noted, "We specialize with individuals living in rural
settings of South Africa. In South Africa there are ongoing public health and
media campaigns to increase public awareness and uptake of HIV testing in an
attempt to curb the spread of the epidemic. We anticipate that offering a
non-invasive rapid test may quite possibly result in an enhanced uptake of
testing, mostly as a result of it being more acceptable and painless, even more
so for children. In our study, the technique was clearly preferred over
finger-sticks by the health care providers."
Dr. Pravi Moodley, Acting Head of the Department of Virology at the University of
KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa and a
co-author of the poster commented, "The sampling of oral fluid for HIV antibody
rapid testing in resource constrained settings has advantages over the
conventional finger-prick blood which is currently used for HIV antibody rapid
testing. The obtaining of an oral fluid sample is much simpler since a community
health worker requiring minimal training will be able to obtain the sample. It is
also much safer since no sharps and sharps containers are necessary, obviating
the need for intensive health and safety training which may unnecessarily consume
financial and human resources in already resource constrained settings."
Further, our field evaluation of Calypte's Aware(TM) HIV-1/2 OMT Rapid Test
showed excellent correlation with blood samples," concluded Dr. Moodley.
How many times have you said this?
Would'nt it be nice if these crooks would simply say "I am running for congress to scam the public for every dime I can steal",lol.